|Exhibit 99.1
|------------



|BRADLEY PHARMACEUTICALS UPDATES
STATUS OF PATENT LAWSUIT
|--------------------------------------------------------



|Fairfield, NJ - April 25, 2003 - BRADLEY
PHARMACEUTICALS, INC. (NASDAQ: BPRX) today announced that its motion for a preliminary
injunction preventing Dermik Laboratories and Aventis Pharmaceuticals from allegedly
infringing aspects of Bradleys patent  concerning the composition and use of its
proprietary Carmol® 40 urea brand line has been denied.
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|Bradley Pharmaceuticals President and CEO,
Daniel Glassman, stated, While the U.S. District Court for the District of New
Jerseys  ruling with respect to our request for a preliminary injunction is
disappointing, the Courts ruling is limited to our request for a  preliminary injunction
only. From the commencement of our lawsuit, Bradley recognized the extraordinary nature
of the injunctive  relief we were seeking and the extremely high burden of proof that we
would have to satisfy at this early stage of litigation.  Bradley continues to review
with its advisors its strategies and alternatives with respect to this lawsuit.
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|Please visit Bradley
Pharmaceuticals web site  at: www.bradpharm.com
|--------------------------------------------------------------------



|Except for historical and factual information,
this press release contains forward-looking statements within the meaning of
the  Private Securities Litigation Reform Act of 1995.  These forward-looking statements
include statements that address activities,  events or developments that Bradley expects,
believes or anticipates will or may occur in the future, such as earnings estimates and
predictions of future financial performance.  All forward-looking statements are based on
assumptions made by Bradley based on its  experience and perception of historical trends,
current conditions, expected future developments and other factors it believes are
appropriate under the circumstances.  These statements are subject to numerous risks and
uncertainties, many of which are beyond  Bradleys control, including Bradleys ability
to maintain CARMOL® sales and bear the outcome of related pending litigation,
effectively purchase or integrate new products into its portfolio or effectively react to
other risks described from time to time in  Bradleys SEC filings.  Further, Bradley
cannot predict the impact on its business of any future approvals of generic versions of
its  products or of other competing products.  No forward-looking statement can be
guaranteed, and actual results may differ materially  from those projected.  Bradley
undertakes no obligation to publicly update any forward-looking statement, whether as a
result of new  information, future events or otherwise.
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  | 
| |  | 



---